HK CEO & Director Dealings (26 Jan 2024): Sun Hung Kai, Wuxi Bio, Sichuan Kelun-Bio, Wisdom Sports
The data in this insight is collated from the "shareholding disclosure" link on the HKEx website. These insights also flag those companies where...
509 Views
Remegen (9995.HK/688331.CH) - The Real Reasons for the Stock Price Collapse and the Future Prospects
RemeGen's 23Q4 results will miss expectation, leading to poor performance for 2023.The pain point isn't cashflow shortage but weak...
336 Views
China's Rising Role in Global ADC Partnership Wave - Opportunities and Risks Behind the Gold Rush
As China's ADCs continue to gain recognition from global buyers,the position of Chinese pharmaceutical companies is undergoing fundamental...
486 Views
China Healthcare Weekly (Sep.22) - Medical Device VBP, Restore Optimism on Healthcare, Biokin Pharma
National VBP of intraocular lens/sports medicine medical consumables begins.Investors will maintain optimism when understand the logic behind...
557 Views